Bimatoprost in Diabetic Patients: Glaucoma Safety & Macular Edema Risk

Bimatoprost 0.03% ophthalmic solution is approved for glaucoma/ocular hypertension in diabetic patients. However, diabetics have a higher baseline risk of macular edema, especially post-cataract surgery. Clinical trials show bimatoprost does not significantly increase this risk, but monitoring is prudent:

  • Baseline OCT macula before starting.
  • Periodic OCT if diabetic retinopathy or prior cataract surgery.
  • Discontinue if macular edema develops/worsens.

Overall, benefit of IOP lowering outweighs risk in most diabetic glaucoma patients.

Diabetes - Related Articles